Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?

J Clin Oncol. 2024 Aug 10;42(23):2736-2740. doi: 10.1200/JCO.23.02301. Epub 2024 May 16.

Authors

Dan Stetson¹, Paul Labrousse¹, Hugh Russell¹, David Shera², Chris Abbosh³, Brian Dougherty¹, J Carl Barrett¹, Darren Hodgson³, James Hadfield⁴

Affiliations

¹ Translational Medicine, Oncology R&D, AstraZeneca, Waltham, MA.
² Oncology Biometrics, AstraZeneca, Gaithersburg, MD.
³ Cancer Biomarker Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
⁴ Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

PMID: 38754043
DOI: 10.1200/JCO.23.02301

No abstract available

MeSH terms

Biomarkers, Tumor / genetics
High-Throughput Nucleotide Sequencing
Humans
Neoplasm, Residual*

Substances

Biomarkers, Tumor